U.S. markets closed

Ionis Pharmaceuticals, Inc. (IONS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
50.24+0.20 (+0.40%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close50.04
Open50.00
Bid48.80 x 800
Ask50.28 x 1200
Day's Range49.66 - 50.31
52 Week Range39.32 - 66.22
Volume688,790
Avg. Volume987,126
Market Cap7.018B
Beta (5Y Monthly)1.45
PE Ratio (TTM)96.99
EPS (TTM)0.52
Earnings DateFeb 24, 2021 - Mar 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est67.11
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-13% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development
    PR Newswire

    Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development

    Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the biopharmaceutical company AstraZeneca has licensed ION455, an investigational antisense medicine being developed as a potential treatment for nonalcoholic steatohepatitis (NASH). ION455 is the second medicine for the treatment of NASH that Ionis has partnered with AstraZeneca. The companies have also partnered on ION839 (AZD2693), which is designed to inhibit the production of patatin-like phospholipase domain-containing 3 (PNPLA3) protein, a major genetic determinant of NASH progression. Separately, Ionis is also developing a wholly owned NASH program. ION224 is designed to reduce the production of DGAT2, or diacylglycerol acyltransferase 2, for treating patients with NASH. ION224 is one of more than 20 medicines in the growing Ionis-owned pipeline that the company is prioritizing and preparing for commercialization.

  • Promising new data for Ionis' antisense medicine targeting PCSK9 presented at American Heart Association (AHA) Scientific Sessions 2020
    PR Newswire

    Promising new data for Ionis' antisense medicine targeting PCSK9 presented at American Heart Association (AHA) Scientific Sessions 2020

    Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that new data for ION449, an investigational antisense medicine designed to reduce plasma levels of proprotein convertase subtilisin/kexin type 9, or PCSK9, were presented today at the American Heart Association (AHA) Scientific Sessions. PCSK9 is integrally involved in the regulation of LDL-cholesterol (LDL-C). Genetic studies have shown that individuals with life-long reduction of LDL-C due to reduced function of PCSK9 have substantially reduced risk of cardiovascular disease.

  • Ionis' pioneering antisense technology to be featured in multiple presentations at American Heart Association (AHA) Scientific Sessions 2020
    PR Newswire

    Ionis' pioneering antisense technology to be featured in multiple presentations at American Heart Association (AHA) Scientific Sessions 2020

    Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the upcoming presentations of clinical and non-clinical data for several of its investigational antisense medicines for cardiovascular disease at the American Heart Association (AHA) Scientific Sessions 2020, to be held virtually November 13-17, 2020.